NCT05231590已完成3 期
A Non-Randomized, Three-Armed, Open-Label, Parallel-Group, Non-Inferiority Trial to Compare the Immunogenicity and Safety of an Adjuvanted Recombinant Spike Protein COVID-19 Vaccine (SpikoGen) in Children Aged 5 to <12 Years and 12 to <18 Years With Adults Aged 18 to 40 Years
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Cinnagen
- 入组人数
- 581
- 试验地点
- 2
- 主要终点
- Percentage of participants with seroconversion for SARS-CoV-2 neutralizing antibodies
研究概览
简要总结
This was a non-randomized, three-armed, open-label, parallel-group, non-inferiority trial designed to compare the immunogenicity and safety of the SpikoGen COVID-19 vaccine in children aged 5 to <12 years and 12 to <18 years with adults aged 18 to 40 years. Children aged 12 to <18 years and adults received 25 µg of the recombinant protein together with 15 mg of Advax-SM. Children aged 5 to <12 years received a half-dose of the adjuvanted vaccine. The injection was given in two doses with a 21-day interval in the deltoid muscle of the non-dominant arm. The vaccine immunogenicity was evaluated at 14 days after the second dose. Solicited adverse events were recorded for 7 days after each vaccination. Unsolicited adverse events were collected through one month after the second dose. Safety monitoring was continued through six months after the second dose in children aged 5 to <12 years and 12 to <18 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 5 Years 至 40 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female between 5 and 40 years of age inclusive
- •Willing and able to comply with all study requirements, including scheduled visits, interventions, and laboratory tests
- •Healthy adults or adults in a stable medical condition, defined as not being hospitalized within 3 months prior to the screening visit
- •Females must not be pregnant or breastfeeding
- •Children with a body mass index equal to or greater than the 3rd percentile for age and sex as per the World Health Organization child growth standards
排除标准
- •Subjects with signs of active SARS-CoV-2 infection at the screening visit.
- •Subjects with epilepsy or a history of febrile seizures
- •Subjects who receive immunosuppressive or cytotoxic medications.
- •Subjects who have a history of severe allergic reactions (e.g., anaphylaxis) to the study vaccine, any components of the study interventions, or any pharmaceutical products.
- •Subjects who have received any other investigational products within 30 days prior to the screening visit or intend to participate in any other clinical studies during the period of this study.
- •Subjects who have been vaccinated with any vaccine or vaccine candidate against SARS-CoV-
- •Subjects who have received any vaccines within 28 days prior to the screening visit or intend to receive any vaccines up to day 14 of the study.
- •Subjects who have any known bleeding disorders or, in the investigator's opinion, have any contraindications for an intramuscular injection.
- •Subjects who have received any blood, plasma, or immunoglobulin products from 90 days prior to the screening visit or intend to receive during the study period.
- •Subjects with any condition that may increase the risk of participating in the study or may interfere with the evaluation of the primary endpoints of the study in the investigator's opinion.
- •Subjects who have donated ≥450 mL of blood or blood products within 28 days prior to the screening visit.
结局指标
主要结局
Percentage of participants with seroconversion for SARS-CoV-2 neutralizing antibodies
时间窗: 14 days after the second dose
As measured by virus neutralization test; the primary aim of this study was to establish non-inferiority of the immunogenicity of SpikoGen COVID-19 vaccine in children aged 5 to \<12 to that in adults
次要结局
- Geometric mean fold rise (GMFR) for SARS-CoV-2 neutralizing antibodies(14 days after the second dose)
- Geometric mean concentration (GMC) for S1 binding IgG antibodies(14 days after the second dose)
- Incidence of serious adverse events (SAEs) and suspected unexpected serious adverse reaction (SUSARs) in children(Up to 6 months after the second dose)
- Percentage of participants with seroconversion for S1 binding IgG antibodies(14 days after the second dose)
- Geometric mean titer (GMT) for SARS-CoV-2 neutralizing antibodies(14 days after the second dose)
- Incidence of solicited adverse events(For 7 days after each dose)
- Geometric mean fold rise (GMFR) for S1 binding IgG antibodies(14 days after the second dose)
- Incidence of unsolicited adverse events(Up to 1 month after the second dose)
- Geometric mean ratio (GMR) for S1 binding IgG antibodies(14 days after the second dose)
- Geometric mean ratio (GMR) for SARS-CoV-2 neutralizing antibodies(14 days after the second dose)
研究者
研究点 (2)
Loading locations...
相似试验
撤回
不适用
A randomized study in Maori / Pacific Islander smokers comparing exposure to selected harmful and potentially harmful constituents (HPHCs) of those switching to the iQOS device, continuing with conventional cigarette smoking and smoking abstinence.SmokingPublic Health - Other public healthMental Health - AddictionACTRN12617000232336Optimal Clinical Trials180
进行中（未招募）
不适用
A phase 3, randomized, open-label, two-arm, parallel-group, multicenter, multinational trial to compare the efficacy of rotigotine transdermal patch to that of ropinirole on early morning motor impairment and sleep disorders in subjects with early-stage, idiopathic Parkinson s diseaseEUCTR2004-002609-66-ITSCHWARZ PHARMA60
进行中（未招募）
不适用
A phase 3, randomized, open-label, two-arm, parallel-group, multicenter, multinational trial to compare the efficacy of rotigotine transdermal patch to that of ropinirole on early morning motor impairment and sleep disorders in subjects with early-stage, idiopathic Parkinson's diseaseParkinson's DiseaseEUCTR2004-002609-66-DESchwarz Biosciences GmbH60
进行中（未招募）
1 期
A phase 3 study comparing safety and efficacy of LY versus titrated insulin degludec on glycemic control in Patients with type 2 DiabetesMedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 2EUCTR2018-003422-84-ITELI LILLY & COMPANY, LILLY CORPORATE CENTER1,420
进行中（未招募）
1 期
A phase 3 study comparing safety and efficacy of LY versus titrated insulin degludec on glycemic control in Patients with type 2 Diabetes.Diabetes Mellitus, Type 2EUCTR2018-003422-84-PLEli Lilly and Company1,420